Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ABBOTT EXTENDING INFUSION PUMP LINE

Executive Summary

ABBOTT EXTENDING INFUSION PUMP LINE with LifeCare 1500 ambulatory microinfuser, developed and manufactured by Parker Hannifin, Abbott an- nounced in a May 15 release. Abbott said it "signed an agreement to market an ambulatory medication infusion pump developed by Parker Hannifin. . .to further extend its leading line of products that deliver intravenous fluids and drugs to patients electronically." Parker Hannifin said that Abbott would have exclusive marketing rights to the device as long as certain undisclosed conditions are met. Parker Hannifin will produce the device, which will either be leased or sold to physicians and hospitals at a cost ranging between $1,400 and $2,000, for Abbott. The microinfusion pump, Abbott's fourth electronic flow device in the LifeCare line, will be marketed separately from Abbott drug products, the firm said. Abbott's other pump devices include the LifeCare Model 4 pump, micro pump, 1050 volumetric controller, and a patient-controlled analgesia system. The programmable electronic infusion device, approved by the FDA 16 months ago, "will be used to provide drugs to patients being treated for cancer, pain and infectious diseases," the release states. The device is "smaller than a business card" and weighs "less than 2-1/2 ounces," according to the release.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth
UsernamePublicRestriction

Register

PS008329

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel